Abstract Library

#3912 Development of a mobile app for patients with neuroendocrine neoplasms: A collaborative project between United Kingdom NET Society and Neuroendocrine Tumour Patient Foundation

Introduction: Digital technology has an important role in the management of long term conditions.

Conference:

Presenting Author: Srirajaskanthan R

Authors: Srirajaskanthan R, Alaghband N, Ramage J, Solis B, Virk J,

Keywords: PROMs, Mobile Health, Neuroendocrine Tumor, Charity, patient focussed, bespoke, QoL,

#3824 A rare clinical case of giant pituitary ACTH adenoma

Introduction: Cushing's disease is a neuroendocrine disease that is associated with ACTH-secreting pituitary microadenomas whereas macro- and giant adenomas are less common.

Conference:

Presenting Author:

Authors: Lastovkina A, Ilovaiskaya I, Komerdus I, Motrenko A, Zakharova P,

Keywords: Cushing's disease, giant corticotropinoma, hypercortisolism,

#3310 Ectopic Cushing’s syndrome: Experience from a tertiary care center

Introduction: Neuroendocrine neoplasms (NENs) causing ectopic Cushing’s syndrome (ECS) are relatively rare and very challenging to treat.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Lase I

Authors: Lase I, Grönberg M, Strele I, Kozlovacki G, Norlën O,

Keywords: Ectopic Cushing’s syndrome, ACTH, neuroendocrine, hypercortisolism, multiple hormone secretion, bilateral adrenalectomy,

#3108 Challenges in primary neuroendocrine tumor identification

Introduction: ACTH secreting neuroendocrine tumors can be a pituitary adenoma, an ectopic tumor, or very rarely - pituitary carcinoma. The identification of the primary neuroendocrine tumor can be challenging or even unsuccessful.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Butkus M

Authors: Sereikaitė L, Butkus M, Jasinskaitė M, Žilaitienė B,

Keywords: cushing syndrome, metastatic neuroendocrine tumor, pituitary adenoma, pituitary carcinoma,

#2887 CHOI Criteria Are More Accurate Than RECIST in Advanced Pancreatic Neuroendocrine Tumors Treated with Sunitinib: Data from the CRIPNET-GETNE1504 Study

Introduction: Comparative data suggest greater accuracy of Choi vs RECIST in some cancers such as pancreatic neuroendocrine tumors (panNET) treated with antiangiogenic agents.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Jimenez-Fonseca P, Fernandez del Valle A, Solis M, Garcia Carbonero R, Custodio A,

Keywords: CHOI, RECIST, Response, Sunitinib, Survival,